Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.

Barrail-Tran A, Goldwirt L, Gelé T, Laforest C, Lavenu A, Danjou H, Radenne S, Leroy V, Houssel-Debry P, Duvoux C, Kamar N, De Ledinghen V, Canva V, Conti F, Durand F, D'Alteroche L, Botta-Fridlund D, Moreno C, Cagnot C, Samuel D, Fougerou-Leurent C, Pageaux GP, Duclos-Vallée JC, Taburet AM, Coilly A.

Eur J Clin Pharmacol. 2019 Aug 5. doi: 10.1007/s00228-019-02725-x. [Epub ahead of print]

PMID:
31384986
2.

Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment.

Gelé T, Furlan V, Taburet AM, Pallier C, Becker PH, Goujard C, Gasnault J, Barrail-Tran A, Chéret A.

Open Forum Infect Dis. 2019 Jun 3;6(6):ofz174. doi: 10.1093/ofid/ofz174. eCollection 2019 Jun.

3.

Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.

Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group.

HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27.

PMID:
30688008
4.

Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood.

Gonzales E, Matarazzo L, Franchi-Abella S, Dabadie A, Cohen J, Habes D, Hillaire S, Guettier C, Taburet AM, Myara A, Jacquemin E.

Orphanet J Rare Dis. 2018 Oct 29;13(1):190. doi: 10.1186/s13023-018-0920-5.

5.

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.

Atwine D, Bonnet M, Taburet AM.

Br J Clin Pharmacol. 2018 Aug;84(8):1641-1658. doi: 10.1111/bcp.13600. Epub 2018 May 22. Review.

6.

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

Madelain V, Guedj J, Mentré F, Nguyen THT, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02093-17. doi: 10.1128/AAC.02093-17. Print 2018 Jan. No abstract available.

7.

Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.

Eloy P, Tessier A, Fan-Havard P, Chou M, Verstuyft C, Taburet AM, Haas DW, Bertrand J; ANRS12154 Study Group.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00733-17. doi: 10.1128/AAC.00733-17. Print 2017 Dec.

8.

Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.

Antonini TM, Coilly A, Rossignol E, Fougerou-Leurent C, Dumortier J, Leroy V, Veislinger A, Radenne S, Botta-Fridlund D, Durand F, Houssel-Debry P, Kamar N, Canva V, Perré P, De Ledinghen V, Rohel A, Diallo A, Taburet AM, Samuel D, Pageaux GP, Duclos-Vallée JC; ANRS C023 CUPILT study group.

Transplantation. 2018 Jan;102(1):119-126. doi: 10.1097/TP.0000000000001928.

PMID:
28846559
9.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Nguyen TH, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group.

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

10.

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Madelain V, Guedj J, Mentré F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01305-16. doi: 10.1128/AAC.01305-16. Print 2017 Jan. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

11.

Disseminated intravascular coagulation following administration of sunitinib.

Olivo A, Noël N, Besse B, Taburet AM, Lambotte O.

Mol Clin Oncol. 2016 Jul;5(1):121-123. Epub 2016 May 11.

12.

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.

13.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Réné Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum in: PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D’Ortenzio, Eric]. PLoS Med. 2016 Jun;13(6):e1002066.

14.

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, Mentré F.

Clin Pharmacokinet. 2016 Aug;55(8):907-23. doi: 10.1007/s40262-015-0364-1. Review.

15.

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

Barrail-Tran A, Vincent C, Furlan V, Rosa I, Rosenthal E, Cheret A, Molina JM, Taburet AM, Piroth L; ANRS HC30 QUADRIH Study Group.

Antimicrob Agents Chemother. 2015 Dec;59(12):7903-5. doi: 10.1128/AAC.01603-15. Epub 2015 Oct 5.

16.

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.

Taburet AM, Sauvageon H, Grinsztejn B, Assuied A, Veloso V, Pilotto JH, De Castro N, Grondin C, Fagard C, Molina JM.

Clin Infect Dis. 2015 Oct 15;61(8):1328-35. doi: 10.1093/cid/civ477. Epub 2015 Jun 23.

PMID:
26105170
17.

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.

Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group.

Clin Infect Dis. 2015 Sep 1;61(5):817-25. doi: 10.1093/cid/civ381. Epub 2015 May 14.

PMID:
25977266
18.

Favipiravir for children with Ebola.

Bouazza N, Treluyer JM, Foissac F, Mentré F, Taburet AM, Guedj J, Anglaret X, de Lamballerie X, Keïta S, Malvy D, Frange P.

Lancet. 2015 Feb 14;385(9968):603-604. doi: 10.1016/S0140-6736(15)60232-X. No abstract available.

PMID:
25706078
19.

Telaprevir enhances ribavirin-induced anaemia through renal function impairment.

Cotte L, Barrail-Tran A, Vincent C, Valantin MA, Fournier I, Lacombe K, Chevaliez S, Aboulker JP, Taburet AM, Molina JM; ANRS HC26 study group.

Antivir Ther. 2015;20(5):479-86. doi: 10.3851/IMP2929. Epub 2015 Jan 6.

PMID:
25560644
20.

Dose regimen of favipiravir for Ebola virus disease.

Mentré F, Taburet AM, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D.

Lancet Infect Dis. 2015 Feb;15(2):150-1. doi: 10.1016/S1473-3099(14)71047-3. Epub 2014 Nov 28. No abstract available.

PMID:
25435054
21.

Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.

Lecefel C, Eloy P, Chauvin B, Wyplosz B, Amilien V, Massias L, Taburet AM, Francois H, Furlan V.

J Clin Pharm Ther. 2015 Feb;40(1):119-20. doi: 10.1111/jcpt.12234. Epub 2014 Nov 24.

PMID:
25417855
22.

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.

AIDS. 2015 Jan 2;29(1):53-8. doi: 10.1097/QAD.0000000000000516.

PMID:
25387314
23.

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.

Bhatt NB, Baudin E, Meggi B, da Silva C, Barrail-Tran A, Furlan V, Grinsztejn B, Bonnet M, Taburet AM; ANRS 12146/12214-CARINEMO Study Group.

J Antimicrob Chemother. 2015 Jan;70(1):225-32. doi: 10.1093/jac/dku348. Epub 2014 Sep 18.

24.

Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.

Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Miailhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallée JC, Taburet AM, Teicher E; Agence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group.

Clin Infect Dis. 2014 Oct 15;59(8):1177-84. doi: 10.1093/cid/ciu515. Epub 2014 Jul 3.

PMID:
24992955
25.

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.

Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P; 2013 French HIV expert group.

J Int AIDS Soc. 2014 Jun 17;17:19034. doi: 10.7448/IAS.17.1.19034. eCollection 2014.

26.

Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.

Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM; ANRS 12146-CARINEMO Study Group.

Antimicrob Agents Chemother. 2014 Jun;58(6):3182-90. doi: 10.1128/AAC.02379-13. Epub 2014 Mar 24.

27.

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).

Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak KK, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld AE, Blanc FX, Taburet AM.

PLoS One. 2014 Mar 7;9(3):e90350. doi: 10.1371/journal.pone.0090350. eCollection 2014.

28.

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Lien TT, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD.

PLoS One. 2014 Jan 22;9(1):e84866. doi: 10.1371/journal.pone.0084866. eCollection 2014.

29.

Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.

Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, Taburet AM; CAMELIA (ANRS 1295-CIPRA KH001) Study Group.

J Infect Dis. 2014 Feb 1;209(3):399-408. doi: 10.1093/infdis/jit466. Epub 2013 Aug 29.

PMID:
23990572
30.

Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Peytavin G, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.

AIDS. 2013 Oct 23;27(16):2655-7. doi: 10.1097/01.aids.0000432539.77711.f4.

PMID:
23939241
31.

Characterization of binding of raltegravir to plasma proteins.

Barau C, Furlan V, Yazdanpanah Y, Fagard C, Molina JM, Taburet AM, Barrail-Tran A.

Antimicrob Agents Chemother. 2013 Oct;57(10):5147-50. doi: 10.1128/AAC.00625-13. Epub 2013 Jul 15.

32.

The ethics of a clinical trial when the protocol clashes with international guidelines.

Lan NT, Thu NT, Duc NH, Lan NN, Lien TT, Dung NH, Taburet AM, Laureillard D, Borand L, Quillet C, Lagarde D, Pym A, Connolly C, Lienhardt C, Rekacewicz C, Harries AD.

Public Health Action. 2013 Jun 21;3(2):97-102. doi: 10.5588/pha.13.0017.

33.

Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

Chauvin B, Drouot S, Barrail-Tran A, Taburet AM.

Clin Pharmacokinet. 2013 Oct;52(10):815-31. doi: 10.1007/s40262-013-0075-4. Review.

PMID:
23703578
34.

Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentré F, Goujard C.

Antimicrob Agents Chemother. 2013 May;57(5):2265-71. doi: 10.1128/AAC.02605-12. Epub 2013 Mar 4.

35.

Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.

Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas DW, Taburet AM; ANRS12154 Study Group.

Antimicrob Agents Chemother. 2013 May;57(5):2154-60. doi: 10.1128/AAC.02294-12. Epub 2013 Mar 4.

36.

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.

Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A; CARINEMO study group.

Lancet Infect Dis. 2013 Apr;13(4):303-12. doi: 10.1016/S1473-3099(13)70007-0. Epub 2013 Feb 20.

PMID:
23433590
37.

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS139 TRIO Trial study group.

PLoS One. 2013;8(1):e53621. doi: 10.1371/journal.pone.0053621. Epub 2013 Jan 17.

38.

Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.

Borand L, Laureillard D, Madec Y, Chou M, Pheng P, Marcy O, Sok T, Goldfeld AE, Taburet AM, Blanc FX; CAMELIA ANRS 1295-CIPRA KH001 Study Team.

Antivir Ther. 2013;18(3):419-23. doi: 10.3851/IMP2483. Epub 2012 Dec 12.

PMID:
23237982
39.

Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.

Bertrand J, Chou M, Richardson DM, Verstuyft C, Leger PD, Mentré F, Taburet AM, Haas DW; ANRS 12154 Study Group.

Pharmacogenet Genomics. 2012 Dec;22(12):868-76. doi: 10.1097/FPC.0b013e32835a5af2.

40.

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F; ANRS 134–COPHAR 3 Study Group.

Clin Pharmacol Ther. 2012 Nov;92(5):575-83. doi: 10.1038/clpt.2012.137. Epub 2012 Oct 3.

41.

Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.

Coilly A, Furlan V, Roche B, Barau C, Noël C, Bonhomme-Faivre L, Antonini TM, Roque-Afonso AM, Samuel D, Taburet AM, Duclos-Vallée JC.

Antimicrob Agents Chemother. 2012 Nov;56(11):5728-34. doi: 10.1128/AAC.01151-12. Epub 2012 Aug 20.

42.

Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.

Barau C, Furlan V, Debray D, Taburet AM, Barrail-Tran A.

Br J Clin Pharmacol. 2012 Sep;74(3):515-24. doi: 10.1111/j.1365-2125.2012.04213.x.

43.

Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.

Trancart S, Charreau I, Marchou B, Bocquentin M, Molina JM, Izopet J, Tangre P, Aboulker JP, Taburet AM; ANRS 106 Study Group.

Antimicrob Agents Chemother. 2012 Mar;56(3):1655-7. doi: 10.1128/AAC.05452-11. Epub 2011 Dec 27.

44.

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.

Valantin MA, Lambert-Niclot S, Flandre P, Morand-Joubert L, Cabiè A, Meynard JL, Ponscarme D, Ajana F, Slama L, Curjol A, Cuzin L, Schneider L, Taburet AM, Marcelin AG, Katlama C; MONOI ANRS 136 Study Group.

J Antimicrob Chemother. 2012 Mar;67(3):691-5. doi: 10.1093/jac/dkr504. Epub 2011 Dec 7.

PMID:
22160145
45.

Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study.

Launay O, Tod M, Tschöpe I, Si-Mohamed A, Bélarbi L, Charpentier C, Goujard C, Taburet AM, Lortholary O, Leroy V, Bélec L; ANRS EP24 GYNODYN Study Group.

Antivir Ther. 2011;16(6):843-52. doi: 10.3851/IMP1856.

PMID:
21900716
46.

[Evidence-based therapeutic drug monitoring for indinavir].

Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Review. French.

PMID:
21819808
47.

[Evidence-based therapeutic drug monitoring of lopinavir].

Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):231-8. doi: 10.2515/therapie/2011034. Epub 2011 Aug 9. Review. French.

PMID:
21819807
48.

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

Ahoua L, Guenther G, Rouzioux C, Pinoges L, Anguzu P, Taburet AM, Balkan S, Olson DM, Olaro C, Pujades-Rodríguez M.

BMC Pediatr. 2011 Jul 26;11:67. doi: 10.1186/1471-2431-11-67.

49.

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.

Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, Tangre P, Aboulker JP, Taburet AM, Molina JM, Massip P, Marchou B, Izopet J; ANRS 106-Window Study Team.

PLoS One. 2011;6(6):e21655. doi: 10.1371/journal.pone.0021655. Epub 2011 Jun 27.

50.

Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.

Barau C, Barrail-Tran A, Hemerziu B, Habes D, Taburet AM, Debray D, Furlan V.

Liver Transpl. 2011 Oct;17(10):1152-8. doi: 10.1002/lt.22364.

Supplemental Content

Loading ...
Support Center